Muhammad Zohair

First Habib Modaraba (FHAM)

Sector

MODARABAS

Chase Research
research@chasesecurities.com
+92-21-35293054-60

Symbol: **FHAM**
Current Price: **PKR 28.00**
Market Cap (PKR bn): **3.10**
Total Shares (mn): **110.83**
Free Float (mn): **94.20**
52 Week High: **PKR 37.40**
52 Week Low: **PKR 26.50**

First Habib Modaraba (FHAM) reported earnings per share of PKR 6.75 for FY26, compared to earnings per share of PKR 8.13 in FY25. Furthermore, in 4QFY26, the company reported earnings per share of PKR 1.43, compared to earnings per share of PKR 2.22 in the same period last year (SPLY).

As of June 2026, the company's financing exposure stood at 15.07% in pharmaceuticals, 13.48% in consumer finance, 11.34% in services, and 10.52% in food and allied industries.

The company's financing asset portfolio reached an all-time high of PKR 40.1 billion, the highest level since the commencement of business operations.

Management has requested regulatory permission to allow private modarabas. This would require amendments to the existing regulatory framework and, if approved, could pave the way for unlisted modarabas to enter the market.

PKR 'Mn	FY25	FY26	YoY	4QFY25	4QFY26	YoY
Other income	226	225	0%	62	86	39%
Income from other activities	4,972	4,851	-2%	1,162	1,293	11%
Total income	**5,198**	**5,075**	**-2%**	**1,224**	**1,380**	**13%**
Finance cost	-3,322	-3,351	1%	-743	-937	26%
Administrative and general expenses	-298	-336	13%	-101	-103	2%
Other provisions	-138	8	N/A	7	3	-57%
Others charges	0	0	N/A	0	0	N/A
Non-recurring items	-169	-163	-4%	-45	-40	-11%
Profit before tax	1,271	1,233	-3%	341	302	-11%
Taxation	-369	-485	31%	-96	-144	50%
Profit after tax	**901**	**748**	**-17%**	**246**	**159**	**-35%**
EPS - Basic	8.13	6.75		2.22	1.43	
DPS	2.25	2.25		2.25	2.25	

Important Disclosures

Disclaimer:

This report has been prepared by Chase Securities Pakistan (Private) Limited and is provided for information purposes only. Under no circumstances, this is to be used or considered as an offer to sell or solicitation or any offer to buy. While reasonable care has been taken to ensure that the information contained in this report is not untrue or misleading at the time of its publication, Chase Securities makes no representation as to its accuracy or completeness and it should not be relied upon as such. From time to time, Chase Securities and/or any of its officers or directors may, as permitted by applicable laws, have a position, or otherwise be interested in any transaction, in any securities directly or indirectly subject of this report Chase Securities as a firm may have business relationships, including investment banking relationships with the companies referred to in this report This report is provided only for the information of professional advisers who are expected to make their own investment decisions without undue reliance on this report and Chase Securities accepts no responsibility whatsoever for any direct or indirect consequential loss arising from any use of this report or its contents At the same time, it should be noted that investments in capital markets are also subject to market risks This report may not be reproduced, distributed or published by any recipient for any purpose.